Results 161 to 170 of about 103,961 (275)

A case series of immune checkpoint inhibitor-induced bullous pemphigoid successfully treated with dupilumab and evidence for the BP180 midportion epitope as a preferential autoantigenic target. [PDF]

Front Med (Lausanne)
Didona D, Mariotti F, Pira A, Didona B, Hertl M, Di Zenzo G.   +5 more
europepmc   +1 more source

Multifunctional Role of Mitochondrial Fatty Acid Oxidation in Cancer Immunotherapy and Aging

Cancer Science, EarlyView.
Recent studies have highlighted the complex interplay between tumor immunity, aging, and inflammation. Mitochondrial FAO is a major hub of this physiological interplay. ABSTRACT Recent studies have demonstrated the intricate relationship between tumor immunity, aging, and inflammation.
Koji Kitaoka, Shuhei Hirose, Yu Wang, Tomonori Yaguchi, Kenji Chamoto   +4 more
wiley   +1 more source

Adverse events associated with the use of nivolumab in the middle-aged and older population (>45 years): A pharmacovigilance analysis based on the FAERS database. [PDF]

Medicine (Baltimore)
Xu L, Xie RX, Cai SS, Yang DF, Wu CG, Wang CH.   +5 more
europepmc   +1 more source

Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer. [PDF]

Clin Cancer Res
Guercio BJ, Pietzak EJ, Ravichandran V, Chen JF, Shah RH, Peters V, Regazzi AM, Niglio SA, Aggen DH, Funt SA, Donahue TF, Goh AC, Cha EK, Wong P, Richards AL, Cobbs CC, Donat SM, Dalbagni G, Bochner BH, Iyer G, Donoghue MTA, Ostrovnaya I, Al-Ahmadie HA, Rosenberg JE, Teo MY.   +24 more
europepmc   +1 more source

Choosing between Nivo‐AVD and BrECADD: Hodgkin lymphoma's new era

British Journal of Haematology, EarlyView.
Edward R. Scheffer Cliff, Sean McKeague, Michael J. Dickinson   +2 more
wiley   +1 more source

Perioperative immunotherapy for advanced resectable melanoma: a cost-effectiveness analysis. [PDF]

BMC Health Serv Res
Rui M, Wei Q, Wang Y, You JHS.
europepmc   +1 more source

Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Adjuvant immune checkpoint inhibitors (ICI) and targeted therapy (TT) have revolutionized treatment management for patients with melanoma. However, the current German S3 guideline does not differentiate between patients with and without adjuvant therapy in its recommendations for imaging intervals and follow‐up monitoring, leading to
Markus Reitmajer, Elisabeth Livingstone, Lucie Heinzerling, Kai‐Martin Thoms, Frank Meiss, Markus V. Heppt, Anja Gesierich, Konstantin Drexler, Friedegund Meier, Max Schlaak, Andrea Forschner, Lisa Zimmer   +11 more
wiley   +1 more source

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0. [PDF]

J Immunother Cancer
McKay RR, Ajmera A, Atkins MB, Barata PC, Bergerot C, Bukavina L, Choueiri TK, Desai A, Hakimi AA, Poteat S, Powles T, Rini BI, Shuch B, Signoretti S, Siva S, Xu W, Yip W, Zhang T, Pal SK.   +18 more
europepmc   +1 more source

Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Complete lymph node dissection (CLND) is the standard of care in patients with regional nodal melanoma macrometastasis. However, evidence on surgical procedures in the era of adjuvant systemic therapies is lacking. Patients and Methods This retrospective multi‐center study included stage IIIB–D melanoma patients with ...
Kristine E. Mayer, Jessica C. Hassel, Jannik Sambale, Michael Erdmann, Mihaela‐Anca Sindrilaru, Julia Oberschmied, Alexander Thiem, Dirk Tomsitz, Jana Knuever, Max Schlaak, Carola Berking, Christian Posch, Tilo Biedermann, Oana‐Diana Persa   +13 more
wiley   +1 more source

Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial. [PDF]

ESMO Open
Bedke J, van der Heijden MS, Sonpavde G, Galsky MD, Liao W, Shi L, Blum SI, Mitra S, Patel MY, Powles T.   +9 more
europepmc   +1 more source